Despite being the mainstay of therapy, questions remain as to how to properly use loop diuretics in patients with acute decompensated heart failure (ADHF). In this post, we’ll cover four of the most common mistakes with using loop diuretics in this population.
Of the available agents for treating shock, dopamine remains unusually popular. Although the drug’s varying effects at different doses are thought to afford it several advantages compared to other vasoactive agents, in this post I’ll share three reasons why you should consider replacing dopamine in your practice.
Evidence from randomized controlled trials has demonstrated that the cornerstone pharmacologic therapies used in the management of chronic heart failure with reduced ejection fraction (HFrEF) do not confer the same benefits in patients with preserved ejection fraction (HFpEF). So why do we enroll both subgroups in trials of acute decompensated heart failure (ADHF)? In this entry, we’ll explore differences in pathophysiology between HFrEF and HFpEF and how they may result in variable responses to pharmacologic therapies commonly used in ADHF, particularly diuretics and vasodilators.
In TACTICS-HF, tolvaptan failed to provide a clinically meaningful benefit in patients with acute decompensated heart failure, although patients were enrolled without respect to serum sodium concentrations. Given a consistent trend of disappointing results, does a routine role for the drug exist now or in the future?
In Part 1 of this two-part series, we highlighted some of the limitations of the Diuretic Optimization Strategies Evaluation (DOSE) trial as well as populations in whom continuous infusions of loop diuretics may have advantages over intermittent boluses. In Part 2, we will review some of the disadvantages associated with continuous infusions, as well as pearls for optimally managing them in patients with acute decompensated heart failure.
In the Diuretic Optimization Strategies Evaluation (DOSE) trial, intravenous boluses of loop diuretics were shown to as efficacious and safe as continuous infusions in patients with acute decompensated heart failure. However, the heterogeneity of the population enrolled in DOSE makes it difficult to identify patient populations who might actually benefit from one strategy over another. In Part 1 of this two-part series, we’ll explore several potential populations in whom continuous infusions may be beneficial over intermittent boluses.
The Eighth National Joint Committee recommends a thiazide-type diuretic as one of the first line treatment options for patients with hypertension. However, there is substantial evidence to support the use of a thiazide-like diuretic (e.g., chlorthalidone) over a thiazide diuretic (e.g., hydrochlorothiazide or HCTZ). In this piece, we review the data on why thiazide-like agents should be preferred in this setting.